share_log

Apollomics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Mar 4 20:40
Summary by Futu AI
On March 4, 2024, Apollomics Inc., a clinical-stage biopharmaceutical company, announced the appointment of Matthew Plunkett, Ph.D., as its new Chief Financial Officer (CFO). Dr. Plunkett is recognized for his extensive experience in the biopharmaceutical sector, including his recent role as CFO at Aeovian Pharmaceuticals and his leadership in the Nasdaq IPOs of Imago Biosciences and Nkarta Therapeutics. His appointment is seen as a strategic move for Apollomics as the company progresses with its clinical, regulatory, and commercialization plans, particularly for its lead drug candidates vebreltinib and uproleselan. The company, which focuses on developing oncology therapies, has a pipeline of nine drug candidates, with six in clinical development. The announcement was made via a press release, which is furnished with the SEC but not deemed 'filed' for legal purposes.
On March 4, 2024, Apollomics Inc., a clinical-stage biopharmaceutical company, announced the appointment of Matthew Plunkett, Ph.D., as its new Chief Financial Officer (CFO). Dr. Plunkett is recognized for his extensive experience in the biopharmaceutical sector, including his recent role as CFO at Aeovian Pharmaceuticals and his leadership in the Nasdaq IPOs of Imago Biosciences and Nkarta Therapeutics. His appointment is seen as a strategic move for Apollomics as the company progresses with its clinical, regulatory, and commercialization plans, particularly for its lead drug candidates vebreltinib and uproleselan. The company, which focuses on developing oncology therapies, has a pipeline of nine drug candidates, with six in clinical development. The announcement was made via a press release, which is furnished with the SEC but not deemed 'filed' for legal purposes.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.